List of Metrogel drug patents
Metrogel is owned by Galderma Labs Lp.
Metrogel contains Metronidazole.
Metrogel has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Metrogel are:
- US7348317
- US6881726
Metrogel was authorised for market use on 30 June, 2005.
Metrogel is available in gel;topical dosage forms.
Metrogel can be used as once a day topical treatment of the inflammatory lesions of rosacea.
The generics of Metrogel are possible to be released after 21 February, 2022.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7348317 | GALDERMA LABS LP | Aqueous compositions containing metronidazole |
Feb, 2022
(1 year, 1 month ago) | |
| US6881726 | GALDERMA LABS LP | Aqueous compositions containing metronidazole |
Feb, 2022
(1 year, 1 month ago) | |
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 30 June, 2005
Treatment: Once a day topical treatment of the inflammatory lesions of rosacea
Dosage: GEL;TOPICAL
METROGEL family patents
5
United States
3
European Union
2
Russia
1
South Africa
1
Denmark
1
Austria
1
Mexico
1
Australia
1
Hong Kong
1
Germany
1
Argentina
1
Brazil
1
Portugal
1
Cyprus
1
Spain
1
Korea, Republic of
1
China
1
Japan
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic